nach oben

Diabetologia

Erschienen in:

01.12.2003 | Review

Regulation of adipocytokines and insulin resistance

verfasst von: M. Fasshauer, Dr. R. Paschke

Erschienen in: Diabetologia | Ausgabe 12/2003

Einloggen, um Zugang zu erhalten

Abstract

It has long been known that obesity and insulin resistance are linked. Recently, it has been shown that adipocytes secrete several proteins including tumour necrosis factor-α, interleukin-6, resistin, and adiponectin. Since several of these so-called adipocytokines influence insulin sensitivity and glucose metabolism profoundly, they might provide a molecular link between increased adiposity and impaired insulin sensitivity. Thiazolidinediones which decrease insulin resistance and are used in the treatment of Type 2 diabetes seem to mediate part of their insulin-sensitising effects via modulation of adipocytokine expression. Furthermore, hormones such as β-adrenergic agonists, insulin, glucocorticoids, and growth hormone might impair insulin sensitivity at least in part via up-regulation or down-regulation of adipocytokine synthesis. We summarise the current knowledge on how major adipocyte-secreted proteins are regulated by hormones and drugs influencing insulin sensitivity and discuss its implications for insulin resistance and obesity.

Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618PubMed

Saltiel AR (2000) The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 106:163–164PubMed

Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 [Suppl 2]:S10–S15

Stumvoll M, Haring HU (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217–224PubMed

Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374–381

Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR (1999) beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 274:34795–34802CrossRefPubMed

Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M, Kahn CR (2001) Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol 21:319–329CrossRefPubMed

Fasshauer M, Klein J, Ueki K et al. (2000) Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem 275:25494–25501CrossRefPubMed

Patti ME (1999) Nutrient modulation of cellular insulin action. Ann NY Acad Sci 892:187–203

10.

Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481PubMed

11.

Bluher M, Kratzsch J, Paschke R (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24:328–334PubMed

12.

Gerich JE (1998) The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19:491–503PubMed

13.

Ward AM, Fall CH, Stein CE et al. (2003) Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol 58:500–505CrossRef

14.

Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMed

15.

Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R (1986) Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 250:E269–E273PubMed

16.

Smith TR, Elmendorf JS, David TS, Turinsky J (1997) Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 272:E1071–E1079PubMed

17.

Thirone AC, Carvalho CR, Brenelli SL, Velloso LA, Saad MJ (1997) Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues. Mol Cell Endocrinol 130:33–42CrossRefPubMed

18.

Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMed

19.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMed

20.

Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976CrossRefPubMed

21.

Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS (2002) Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 51:1876–1883PubMed

22.

Xu H, Hirosumi J, Uysal KT, Guler AD, Hotamisligil GS (2002) Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 143:1502–1511CrossRefPubMed

23.

Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M (1998) An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 139:4928–4935PubMed

24.

Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885PubMed

25.

Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212–217

26.

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed

27.

Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119PubMed

28.

Okuno A, Tamemoto H, Tobe K et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361PubMed

29.

Sewter CP, Digby JE, Blows F, Prins J, O’Rahilly S (1999) Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 163:33–38PubMed

30.

Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP (1999) The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 84:2126–2133

31.

Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377–1379CrossRefPubMed

32.

Zilberfarb V, Siquier K, Strosberg AD, Issad T (2001) Effect of dexamethasone on adipocyte differentiation markers and tumour necrosis factor-alpha expression in human PAZ6 cells. Diabetologia 44:377–386PubMed

33.

Chen XL, Lee K, Hartzell DL et al. (2001) Adipocyte insensitivity to insulin in growth hormone-transgenic mice. Biochem Biophys Res Commun 283:933–937CrossRefPubMed

34.

Ikeda A, Chang KT, Matsumoto Y et al. (1998) Obesity and insulin resistance in human growth hormone transgenic rats. Endocrinology 139:3057–3063

35.

Bulow B, Ahren B, Erfurth EM (2001) Increased leptin and tumour necrosis factor alpha per unit fat mass in hypopituitary women without growth hormone treatment. Eur J Endocrinol 145:737–742PubMed

36.

Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed

37.

Nonogaki K, Fuller GM, Fuentes NL et al. (1995) Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136:2143–2149

38.

Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399PubMed

39.

Rotter V, Nagaev I, Smith U (2002) Interleukin-6 (IL-6) reduces gene and protein expression of IRS-1 and GLUT4 and is overexpressed in human fat cells from insulin-resistant subjects. Diabetes 51 [Suppl 2]: A303 (Abstract)

40.

Stith RD, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210–215PubMed

41.

Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167–4170PubMed

42.

Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed

43.

Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed

44.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMed

45.

Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684CrossRefPubMed

46.

Fasshauer M, Klein J, Lossner U, Paschke R (2003) Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 35:147–152CrossRefPubMed

47.

Mohamed-Ali V, Flower L, Sethi J et al. (2001) beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86:5864–5869

48.

Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H (2001) Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86:2281–2288PubMed

49.

Vicennati V, Vottero A, Friedman C, Papanicolaou DA (2002) Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 26:905–911CrossRef

50.

Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850

51.

Papanicolaou DA, Petrides JS, Tsigos C et al. (1996) Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 271:E601–E605PubMed

52.

Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Colch) 96:513–523

53.

Sesmilo G, Biller BM, Llevadot J et al. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111–122PubMed

54.

Grunfeld C, Feingold KR (1991) The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3:143–158PubMed

55.

Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMed

56.

Steppan CM, Brown EJ, Wright CM et al. (2001) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98:502–506CrossRefPubMed

57.

Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230CrossRefPubMed

58.

Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 10:1–5PubMed

59.

Nagaev I, Smith U (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561–564CrossRefPubMed

60.

Way JM, Gorgun CZ, Tong Q et al. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651–25653PubMed

61.

Le Lay S, Boucher J, Rey A et al. (2001) Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 289:564–567CrossRefPubMed

62.

Juan CC, Au LC, Fang VS et al. (2001) Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 289:1328–1333CrossRefPubMed

63.

Milan G, Granzotto M, Scarda A et al. (2002) Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10:1095–1103

64.

Fukui Y, Motojima K (2002) Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor alpha. Diabetes Obes Metab 4:342–345CrossRefPubMed

65.

Shojima N, Sakoda H, Ogihara T et al. (2002) Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51:1737–1744PubMed

66.

Haugen F, Jorgensen A, Drevon CA, Trayhurn P (2001) Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 507:105–108CrossRefPubMed

67.

Moore GB, Chapman H, Holder JC et al. (2001) Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 286:735–741CrossRefPubMed

68.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes. FEBS Lett 500:60–63CrossRefPubMed

69.

Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:11252–11256CrossRefPubMed

70.

Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL (2002) Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 296:383–387CrossRefPubMed

71.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 288:1027–1031CrossRefPubMed

72.

Delhanty PJ, Mesotten D, McDougall F, Baxter RC (2002) Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology 143:2445–2448

73.

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289PubMed

74.

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMed

75.

Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703PubMed

76.

Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein. J Biochem (Tokyo) 120:803–812

77.

Fruebis J, Tsao TS, Javorschi S et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMed

78.

Yamauchi T, Kamon J, Waki H et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMed

79.

Yamauchi T, Kamon J, Minokoshi Y et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295CrossRefPubMed

80.

Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313CrossRefPubMed

81.

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMed

82.

Maeda N, Shimomura I, Kishida K et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737PubMed

83.

Kubota N, Terauchi Y, Yamauchi T et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–25866CrossRefPubMed

84.

Ma K, Cabrero A, Saha PK et al. (2002) Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277:34658–34661CrossRefPubMed

85.

Yamauchi T, Kamon J, Waki H et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and apoE deficient mice from atherosclerosis. J Biol Chem 278:2461–2468CrossRefPubMed

86.

Spranger J, Kroke A, Mohlig M et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228CrossRef

87.

Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed

88.

Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935PubMed

89.

Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed

90.

Yang WS, Lee WJ, Funahashi T et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819PubMed

91.

Hulver MW, Zheng D, Tanner CJ et al. (2002) Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861–E865PubMed

92.

Maeda N, Takahashi M, Funahashi T et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099PubMed

93.

Yu JG, Javorschi S, Hevener AL et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMed

94.

Motoshima H, Wu X, Sinha MK et al. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667CrossRefPubMed

95.

Yang WS, Jeng CY, Wu TJ et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380PubMed

96.

Combs TP, Wagner JA, Berger J et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998–1007

97.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 507:142–146PubMed

98.

Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM (2002) Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 367:677–685CrossRefPubMed

99.

Fasshauer M, Kralisch S, Klier M et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045–1050CrossRefPubMed

100.

Kappes A, Loffler G (2000) Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32:548–554PubMed

101.

Staiger H, Tschritter O, Kausch C, Lammers R, Stumvoll M, Haring HU (2002) Human serum adiponectin levels are not under short-term negative control by free fatty acids in vivo. Horm Metab Res 34:601–603CrossRefPubMed

102.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089CrossRefPubMed

103.

Bluher M, Michael MD, Peroni OD et al. (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25–38PubMed

104.

Viengchareun S, Zennaro MC, Pascual-Le TL, Lombes M (2002) Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 532:345–350CrossRefPubMed

105.

Halleux CM, Takahashi M, Delporte ML et al. (2001) Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288:1102–1107PubMed

106.

Makimura H, Mizuno TM, Bergen H, Mobbs CV (2002) Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 283:E1266–E1271

107.

Masuzaki H, Paterson J, Shinyama H et al. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166–2170PubMed

108.

Nishizawa H, Shimomura I, Kishida K et al. (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMed

109.

Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62:413–437

110.

Kellerer M, Lammers R, Fritsche A et al. (2001) Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: a potential mechanism for hyperinsulinaemia-associated leptin resistance. Diabetologia 44:1125–1132CrossRefPubMed

111.

Fernandez-Galaz C, Fernandez-Agullo T, Perez C et al. (2002) Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. Diabetologia 45:997–1003CrossRef

112.

Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327–332PubMed

113.

Hallakou S, Doare L, Foufelle F et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393–1399PubMed

114.

Zhang B, Graziano MP, Doebber TW et al. (1996) Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455–9459PubMed

115.

Kallen CB, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93:5793–5796PubMed

116.

De Vos P, Lefebvre AM, Miller SG et al. (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98:1004–1009PubMed

117.

Mantzoros CS, Qu D, Frederich RC, Susulic VS et al. (1996) Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Diabetes 45:909–914PubMed

118.

Slieker LJ, Sloop KW, Surface PL et al. (1996) Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 271:5301–5304CrossRefPubMed

119.

Rentsch J, Chiesi M (1996) Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett 379:55–59PubMed

120.

Hardie LJ, Rayner DV, Holmes S, Trayhurn P (1996) Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Biochem Biophys Res Commun 223:660–665

121.

Saladin R, De Vos P, Guerre-Millo M et al. (1995) Transient increase in obese gene expression after food intake or insulin administration. Nature 377:527–529PubMed

122.

De Vos P, Saladin R, Auwerx J, Staels B (1995) Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 270:15958–15961PubMed

123.

Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT (2002) Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51:2895–2902PubMed

124.

Asada N, Takahashi Y, Honjo M (2000) Effects of 22K or 20K human growth hormone on lipolysis, leptin production in adipocytes in the presence and absence of human growth hormone binding protein. Horm Res 54:203–207CrossRefPubMed

125.

Norrelund H, Gravholt CH, Englaro P et al. (1998) Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration. Eur J Endocrinol 138:644–652PubMed

126.

Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM (1999) Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf) 50:163–169

127.

Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479PubMed

128.

Damjanovic SS, Petakov MS, Raicevic S et al. (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154PubMed

Titel: Regulation of adipocytokines and insulin resistance
verfasst von: M. Fasshauer
Dr. R. Paschke
Publikationsdatum: 01.12.2003
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 12/2003
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-003-1228-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Regulation of adipocytokines and insulin resistance

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2003

—to: Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC (2003) Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 46:426–428

Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes

Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI

Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells

Diabetologia 1998–2003

Global profiling of double stranded RNA- and IFN-γ-induced genes in rat pancreatic beta cells

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin